ACM
VIVO

AlphaCrest Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

AlphaCrest Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-35,958
Closed -$933K – 1409
2022
Q1 		$933K Buy
+35,958
New +$855K 0.05% 582
2021
Q4 		– Sell
-11,900
Closed -$229K – 1474
2021
Q3 		$229K Buy
+11,900
New +$237K 0.01% 1186
2021
Q2 		– Sell
-10,300
Closed -$270K – 1384
2021
Q1 		$270K Buy
+10,300
New +$245K 0.02% 1048

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VLKIM
Van Lanschot Kempen Investment Management Amsterdam, Netherlands $11.4B AUM 16.77% 1-Year Est. Return

AlphaCrest Capital Management's VIVO Position: Q2 2022 in Review

AlphaCrest Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q2 2022, closing a stake of 35,958 shares — an estimated $933K sold.

AlphaCrest Capital Management first reported a position in VIVO in Q1 2021 and held it in 3 quarters. The position peaked at $933K in Q1 2022. 216 funds tracked by Wall St. Rank hold VIVO as of Q2 2022.

  • AlphaCrest Capital Management reported no remaining Meridian Bioscience Inc position as of Q2 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 35,958 Meridian Bioscience Inc shares in Q2 2022, an estimated $933K.
  • AlphaCrest Capital Management first reported a position in Meridian Bioscience Inc in Q1 2021 and held it in 3 quarters.
  • AlphaCrest Capital Management's Meridian Bioscience Inc position peaked at $933K in Q1 2022.
  • 216 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2022.

Based on AlphaCrest Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.